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and Yolanda Cervantes
Abstract
Objectives. To evaluate the cost and benefits of a national rotavirus childhood vaccination program in 
Mexico. 
Methods. A decision-analysis model was designed to take the Mexican health care system’s perspective 
on a comparison of two alternatives: to vaccinate against rotavirus or not. Using published, national 
data, estimations were calculated for the rotavirus illnesses, deaths, and disability-adjusted life years 
(DALYs) that would be averted and the incremental cost-effectiveness ratios (US$/DALY) of a 
hypothetical annual birth cohort of 2 285 000 children,with certain assumptions made for cost, 
coverage, and efficacy rates.
Results. With 93% coverage and a vaccine price of US$ 16 per course (2 doses), a rotavirus vaccination 
program in Mexico would prevent an estimated 651 deaths (or 0.28 deaths per 1 000 children); 13 833 
hospitalizations (6.05 hospitalizations per 1 000 children); and 414 927 outpatient visits (182 
outpatient visits per 1 000 children) for rotavirus-related acute gastroenteritis (AGE). Vaccination is 
likely to reduce the economic burden of rotavirus AGE in Mexico by averting US$ 14 million (71% of 
the overall health care burden). At a vaccine price of US$ 16 per course, the cost-effectiveness ratio 
would be US$ 1 139 per DALY averted. A reduction in the price of the rotavirus vaccination program 
(US$ 8 per course) would yield a
lower incremental cost-effectiveness ratio of US$ 303 per DALY averted. 
Conclusions.A national rotavirus vaccination program in Mexico is projected to reduce
childhood incidence and mortality and to be highly cost-effective based on the World 
HealthOrganization’s thresholds for cost-effective interventions. 
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Rotavirus is a virus that infects the
small intestine and can lead to life-
threatening acute gastroenteritis (AGE)
in infants and young children world-
wide. Unlike many other enteropatho-
gens, rotavirus affects children in both
developed and developing countries,
regardless of socioeconomic status (1, 
2). However, the risk of dying from
rotavirus-related gastroenteritis (GE) is
greater in lower-income countries due to
various factors, including limited access 
to health care facilities, lower mean age 
at contraction, and malnutrition. Due to 
the widespread nature of rotavirus, its 
high concentration in the feces, and its 
ability to survive in the environment, the 
prevention of rotavirus spread is virtu-
ally impossible, even where the highest 
hygiene standards are followed (2). 
In Mexico, rotavirus is one of the prin-
cipal causes of GE and occurs mainly
during the fall and winter months. It is of
particular concern in pediatric hospitals,
emergency rooms, and outpatients clin-
ics. However, improved availability of
potable water, access to oral rehydration
therapy, and enhanced surveillance of
all diarrheal episodes have reduced the
overall burden of GE in young children
(3). Morbidity rates associated with all
diarrheal diseases decreased from 4 588
per 100 000 children under 5 years of age
in 1999 to 3 383 by 2002, with the great-
est reduction observed among those
under 1 year. There has also been a sig-
nificant decrease in severe diarrheal
episodes among children under 5 years
of age, from 24.8 per 100 hospitalizations
in 1990 to 9.2 in 1995. This represents a
63% reduction (3) and is the most accu-
rate information to date. Overall mortal-
ity due to AGE in children under 5 years
also decreased from 125.3 per 100 000 in
1990 to 19.7 by 2002, an 84% reduction
(3). From 1990–2002, a significant reduc-
tion in mortality was observed in April–
August, from 13.4 per 100 000 children
under 5 years in 1990 to 1.6 in 2002 (3). 
While overall GE morbidity and mor-
tality have declined, the proportion at-
tributable to rotavirus appears to be
increasing (3, 4). The highest mortality
rates for children under 1 year coincided
precisely with the fall and winter season.
A retrospective, cross-sectional study of
15 large cities in Mexico reported that,
annually, 42% of the children seeking
AGE treatment at pediatric hospitals
were rotavirus positive (3). 
This paper presents detailed analyses
of the disease burden and costs of
rotavirus disease among Mexican chil-
dren, and the expected cost-effectiveness
of introducing a national rotavirus vacci-
nation program. These results are part of
a larger study being carried out in Latin
America and the Caribbean, specifically
Argentina, Brazil, Chile, Dominican Re-
public, Honduras, Mexico, Panama, and
Venezuela (5, 6). In contrast to this Re-
gional study, in which estimates were
derived from extrapolated data, this
paper focuses solely on Mexico and uses
country-level epidemiological data and
cost estimates.
MATERIALS AND METHODS
Analytic overview
A diagram of the model used to esti-
mate the economic burden and cost-
effectiveness of rotavirus vaccination is
shown in Figure 1. The boxes identify the
primary inputs needed for the model
(epidemiological, economic, and vaccine
data). The circles represent the intermedi-
ary outputs (health benefit, economic
burden, and net cost savings). The pri-
mary outputs of the model are displayed
in hexagons as cost-effectiveness ratios. In
this study, these ratios are expressed as
the cost per death averted, per disability-
adjusted life years (DALYs) averted, or
per life year gained (LYG). This diagram
provides only a broad representation of
the inputs and outputs of the model. 
A decision-analysis model was devel-
oped in Microsoft Excel® to estimate the
health and economic outcomes of a na-
tional rotavirus vaccination program in a
hypothetical annual birth cohort of chil-
dren for a 5-year period. The net, med-
ical, direct-cost of the vaccination pro-
gram was determined to be the cost of
the vaccination program, minus the ex-
pected averted medical costs (the sav-
ings from reduced use of health care
resources).
The primary perspective for this
analysis was that of the health care sys-
tem. Costs such as non-medical direct
costs or productivity losses to caregivers
were not included in these cost-effective-
ness calculations due to paucity of data.
All cost estimates collected in local
currency were converted to 2007 United
States dollars (US$). Future costs and
DALY estimates were discounted at a
3% rate, as recommended by the U.S.
Panel of Cost-Effectiveness in Health
and Medicine (7) and the World Bank
Global Burden of Disease Project (8). 
The annual birth cohort considered
was 2 285 000 children (9). The age dis-
tribution of rotavirus illness was esti-
mated for each one of the disease out-
comes (deaths, hospitalizations, and
outpatient visits) using published stud-
ies from Mexico and Latin America (10–
20). The estimated number of outcomes
for an annual birth cohort was distrib-
uted as follows: 0–2 months of age, 3–5,
6–8, 9–11, 12–23, 24–35, 36–47, and 48–59. 
Model inputs
Rotavirus disease burden. Disease bur-
den was estimated as the expected num-
ber of rotavirus-associated outcomes 
for a single birth cohort. The risk of
rotavirus-related outpatient visit, hospi-
talization, and death were based on the
cumulative risk of each AGE event dur-
ing the first 5 years of life and the pro-
portion of these events attributed to ro-
tavirus. The cumulative risk of each
event in Mexico was estimated from na-
tional administrative data for the year
2002 (21, 22), and refers to the proportion
of children in a defined population in-
fected with rotavirus at least once before
reaching their 5th year of life. Risk refers
to the proportion of a population for an
FIGURE 1. Model framework depicting rotavirus (RV) vaccine introduction and subse-
quent events that may be experienced by each child, including life-years gained (LYG)
and disability-adjusted life years (DALYs)
Epidemiology
• RV rates
• RV proportion
• Healthcare utilization
Economics
• Hospital per diem
• Visit costs
• Direct costs
• Parent expenses
Vaccine
• Coverage
• Efficacy
• Cost
Health Benefits
• Events
• Deaths
• LYG
• DALYs
Cost-
Effectiveness
• $/DALY averted
• $/deaths averted
• $/LYG
Economic Burden
• $ per cohort
• Medical cost
• Patient cost
Net Cost
Savings
• $ per cohort
event and cumulative is the risk for each
year of age multiplied together.
In brief, the cumulative risk of a rota-
virus outpatient visit was calculated
using data provided by the epidemiol-
ogy unit of the Instituto Mexicano del
Seguro Social (Mexican Social Security
Institute, IMSS). The IMSS reported a
total of 950 231 emergency room/outpa-
tient visits for diarrhea among children
less than 10 years of age, of which an es-
timated 93% were in children less than 
5 years (22). In addition, in 2002, the Sta-
tistics and Information Division of the
Secretaría de Salud/Servicio Social de
Salud (Secretary of Health and Social
Services, SSA), reported 974 129 outpa-
tient visits for the same age group (21).
To calculate the 5-year cumulative risk 
of an outpatient visit for diarrhea, the
total number of diarrheal outpatient
visits for children less than 5 years 
(883 715 + 974 129 = 1 857 844) was di-
vided by the proportion of Mexico’s total
under-1 year population (2 056 853). The
rotavirus-specific outpatient rate was
then calculated assuming that 25% of di-
arrheal outpatient visits were attributed
to rotavirus. This was an average esti-
mate based on data from five published
studies (23–26). The cumulative risk of
an outpatient visit for rotavirus AGE
(265 per 1 000) was calculated by multi-
plying the cumulative risk of an outpa-
tient visit for AGE by the proportion at-
tributed to rotavirus GE.
The cumulative risk of rotavirus AGE
hospitalization was based on national
data for the year 2002 (21, 22), using
codes A00–A09 of the International Classi-
fication of Diseases, 10th Edition (27). The
SSA reported 15 513 hospitalizations for
diarrhea among children less than 5
years of age. In addition, the IMSS re-
ported a total of 16 347 diarrheal hospi-
talizations for children less than 10, of
which 93% occurred in children less than
5. The number of children less than 5
years of age hospitalized for diarrhea 
(30 716) was then divided by the popula-
tion less than 1 year (2 056 853) covered
by both health care systems. The cumu-
lative risk of diarrheal hospitalization
was 0.0176 per child by the 5th birth-
day. The rotavirus proportion (40%) was
based on published estimates (3, 28). The
cumulative risk of hospitalization for ro-
tavirus AGE (7 per 1 000) was then cal-
culated by multiplying the cumulative
risk of AGE hospitalization by the pro-
portion attributed to rotavirus AGE.
The cumulative risk of a rotavirus-
related death was based on 2002 national
data from the Instituto Nacional de Es-
tadística Geografía e Informática (Na-
tional Institute of Statistics, Geography,
and Informatics, INEGI) (4). Approxi-
mately 2 157 deaths due to diarrheal dis-
eases occurred annually in children less
than 5 years of age. By dividing these 
(2 157) by the population less than 1 year
of age (2 056 853), the cumulative risk of
a death due to AGE was calculated to be
1.05 deaths per 1 000 live births. Since
diarrheal mortality data were not spe-
cific to rotavirus, the proportion attribut-
able to rotavirus was assumed to be the
same as the proportion of hospitaliza-
tions attributed to rotavirus (3, 28). The
cumulative risk of death due to rotavirus
AGE (0.42 per 1 000) was calculated by
multiplying the risk of death due to GE
by the proportion of GE deaths attrib-
uted to rotavirus.
Disability-adjusted life years (DALYs).
The disease burden of morbidity and
mortality was also estimated in terms of
DALYs (8). The DALY estimate included
Years of Life Lost (YLL) due to prema-
ture mortality and Years Lived with Dis-
ability (YLD). The DALY loss from mor-
tality (YLL) was calculated based on the
average country-specific life expectancy
at birth (29). The average life expectancy
for males and females is 73.6 and 74.4
years, respectively. Only morbidity from
disease severe enough to require med-
ical care was considered for the calcula-
tion of YLD. Default disability weights
from the global burden of disease study
(8) and the World Health Organization’s
guidelines for cost-effectiveness studies
(30) and estimated rotavirus illness du-
ration of six days (31) were used to cal-
culate YLD. A discount rate of 3% and
age weighting were included (30) to en-
sure comparability.
Rotavirus vaccine efficacy and cover-
age. Estimates of the effectiveness of a
complete vaccination course for rota-
virus disease were based on the results
of the phase III clinical trial of the live-
attenuated human rotavirus vaccine
(GSK Biologicals S.A., Rixensart, Bel-
gium) that was given as two oral doses at
2 and 4 months of age. This was a multi-
center trial conducted in 11 countries of
Latin America, including Mexico. 
The human attenuated rotavirus vac-
cine was first licensed in Mexico in July
2004 and made available to the private
sector in January 2005. In March 2007,
the vaccine was incorporated into the
routine immunization schedule, first by
the IMSS and later, in August 2007, by
the Ministry of Health. Vaccine coverage
has not yet reached the expected 90%.
The efficacy of the human rotavirus
vaccine to prevent rotavirus-related acute
GE (requiring hospitalization) was 85%
(32). Efficacy against outpatient visits
was assumed to be 78%. This represents
the midpoint of 85% efficacy against
rotavirus AGE (32) and 70% efficacy
against any rotavirus GE (33). Efficacy
against death was assumed equal to that
of the most severe cases requiring hospi-
talization (31). For the baseline analysis
it was further assumed that one dose of
the vaccine would have the same effec-
tiveness as a full course during the in-
terdosing period, as demonstrated by a
clinical trial in Latin America (32). For
the baseline analysis, it was further as-
sumed that effectiveness would not de-
cline in the second and subsequent years
following vaccination.
It was assumed that children would
receive the rotavirus vaccine at the same
time as the diphtheria, tetanus, acellular
pertussis, Haemophilus influenzae, inacti-
vated polio vaccine (DTPa + Hib + IPV),
and the hepatitis B vaccine (HBV), which
in Mexico are given at 2 months, 
4 months, and 6 months of age. In the
baseline analysis, national coverage of
the third dose of DTP at 1 year of age for
the year 2003 was estimated to be 92.8%
(34). Rotavirus vaccination would occur
with DTPa + Hib + IPV doses one and
two; however, standardized data are
only available for the coverage of the
third dose (Table 1). As a result, this may
be an underestimation of the actual cov-
erage for doses one and two.
The effectiveness of vaccination was
assessed by combining information on
the expected vaccine coverage and tim-
ing of illness. An annual birth cohort was
followed through the same age periods
previously described. During each pe-
riod, the number of outcomes in the ab-
sence of vaccination was estimated. The
reduction in the number of outcomes
during the same period was estimated
based on the proportion of children with
one or two doses, and the efficacy of one
or two doses. The expected number of
events averted prior to the 5th birthday
was calculated as the sum of outcomes in
each period. The global efficacy of the
vaccine against severe rotavirus GE was
also considered. For this reason, infor-
mation on specific rotavirus serotypes
was not considered in the analyses.
Vaccination costs. All costs are ex-
pressed in 2007 U.S. dollars. Vaccination
costs included the cost of administering
the vaccine, the price of each dose, the
number of doses given (based on cover-
age level), and the expected waste losses
from the vaccination program (10%). The
costs for administering the vaccine in-
cluded the cost of health care personnel
and training, cold chain, storage space,
and public education. Mexico has the re-
quired infrastructure for running a na-
tional rotavirus vaccination program,
based on its extensive history of admin-
istering oral polio vaccine. For this rea-
son, the incremental administration costs
are assumed to be low. A few studies
estimate the cost of immunization for 
the current WHO-recommended vaccines
(35–38); however, no data was found on
the incremental cost of adding another
vaccine. Based on the range of estimates
found in the immunization cost studies
and the assumption that the incremental
cost of administering an additional vac-
cine would be low, the model uses a cost
of US$ 1 per course. The public sector
price per course of the vaccine (2 doses)
was assumed to be US$ 16.
The vaccine price is a key variable in
the cost-effectiveness estimates. For this
reason, vaccine prices from US$ 8–22 
per course were assessed in sensitivity
analysis. The cost of adverse events re-
sulting from the vaccine were not in-
cluded because its safety profile is simi-
lar to a placebo, therefore the cost, if any,
would be negligible (32, 33).
Cost-generating outcomes. The eco-
nomic burden of rotavirus disease in
Mexican children was determined by
combining the estimated number of each
outcome with information on the costs
associated with each. Cost generating
outcomes were estimated based on three
potential sources: the WHO CHOosing
Interventions that are Cost Effective
(WHO-CHOICE) project (39), physician
interviews, and a multicenter hospital-
based rotavirus surveillance study done
prior to a randomized vaccine trial (32). 
The WHO-CHOICE project provides
estimates of the per-diem cost of hospi-
tals, outpatient visits, and health center
visits for 14 epidemiological categories
based on geographical region and mortal-
ity stratum. The per-diem and visit cost-
estimates include items such as the cost 
of the facility, personnel, equipment, and
food, and excludes items such as medica-
tions and diagnostic tests (40). All prices
were adjusted for inflation (41). A hospi-
tal per-diem rate was estimated as an av-
erage of estimates for public primary, sec-
ondary, and tertiary-level facilities, using
the proportions from the multicountry
study (42). The cost of hospitalization
was calculated as the product of the per-
diem cost and a duration of 3.5 days (25,
43, 44). Country-specific outpatient visit
costs were developed by adjusting the
WHO-CHOICE regional estimate pro-
portionally to the country-specific hospi-
tal per-diem cost. 
Six physicians were interviewed to
characterize the typical management of
rotavirus AGE. These physicians repre-
sented the public and private sectors and
the IMSS. Interviews included questions
regarding care for patients with moder-
ate and acute rotavirus GE.
For the present analysis, resource uti-
lization data were based on the surveil-
lance study that was conducted in three
Mexican cities (32), since these were
considered to be the most reliable for
Mexico. This surveillance study col-
lected resource utilization and cost data
in January–June 2003, which covers the
months with the highest rotavirus inci-
dence (December–January) and with the
lowest (March–August) (32). Seven hos-
pitals participated: three in the state of
Mexico (two tertiary level and one sec-
ondary); two in Morelos (both tertiary
level) and two in Durango (one tertiary
level and one secondary level).
Health care costs. For this analysis, costs
associated with episodes requiring hos-
pitalization and outpatient visits were
considered. Health care costs were cal-
culated as the sum of the per-diem or
per-visit cost, the cost of diagnostic tests,
and the cost of medication. The hospital
per-diem cost (US$ 57.45) was estimated
based on one public health care institu-
tion, the Hospital General de Tlalne-
pantla, which was considered to be rep-
resentative of the public health sector
and provided its actual per-diem cost.
The cost-per-stay was calculated by mul-
tiplying the per-diem rate, which in-
cluded hotel costs, food, and non-allied
health personnel, by the mean length-of-
stay (3.4 days). To ensure the estimate
was representative, the mean length-of-
stay was based on the average of 2.8 days
(32) and 4 days (derived from physician
interviews, 2003). 
The cost-per-outpatient visit (US$ 14.99)
was calculated as the mean cost of visit-
ing a pediatrician, emergency room, or
rehydration room based on the propor-
tion seen in each of three outpatient
settings (derived from physician inter-
views, 2003). Approximately 30% of pa-
tients with rotavirus AGE visit a pedia-
trician; 30%, an emergency room; 40%, a
rehydration room. Costs for these three
types of outpatient visits were based on
the average given by the Hospital Gen-
eral de Tlalnepantla. 
Costs associated with diagnostic test-
ing for rotavirus AGE were derived from
estimates provided by the finance de-
partment of the Hospital General de
Tlalnepantla. The total diagnostic cost-
per-patient was calculated by taking the
number of times a particular test is per-
formed and multiplying it by its unit
cost, and then summing the total cost of
all the tests performed on a single pa-
tient. A mean diagnostic cost was calcu-
lated for both, inpatients (US$ 6.27) and
outpatients (US$ 4.95). The most common
diagnostic tests reported were blood
counts, electrolytes, blood gas, and stool
specimens. 
Costs associated with medications
were based on estimates provided by the
pharmacy at the Hospital General de Tlal-
nepantla. The total medication cost per
patient was calculated by multiplying the
cost per dose of each medication used 
by the number of doses given and then,
summing the total cost for all the medica-
tions given to a single patient. A mean
medication cost was calculated for both
inpatients (US$ 9.63) and outpatients 
(US$ 7.29). Medications included intrave-
nous rehydration fluid, antiemetic, anti-
fever, and antibiotic therapies. The input
variables used to perform the base case
analysis are described in Table 1.
Sensitivity and uncertainty analyses
For the present analysis, one-way sen-
sitivity analysis of rotavirus disease-re-
lated and cost inputs was performed for
different scenarios that are likely to in-
fluence the cost-effectiveness of vaccina-
tion (45). These scenarios included high-
and low-end estimates of vaccine price,
disease incidence, and disease-related
costs. Sensitivity analysis was performed
using the current price of US$ 16 per
course. 
Additional results from the phase III
clinical trial conducted in Latin America
(32) suggest that the human rotavirus vac-
cine may reduce AGE of all causes, not
limited to rotavirus, by 42% within the
first year of life. Using age-distribution
data for diarrhea disease, the vaccine effi-
cacy against all causes of AGE was con-
sidered as a separate scenario in the sensi-
tivity analysis.
An uncertainty analysis was con-
ducted to help evaluate the potential im-
pact of this uncertainty on preliminary
quantitative estimates and to assess the
need for additional data collection. The
specific purposes included:
• assessing the range of likely outcomes
of immunization based on the prelim-
inary quantitative analysis;
• identifying specific variables that are
likely to be important and may merit
additional data collection; and,
• providing a preliminary framework
for developing confidence intervals
for final national estimates.
A Monte Carlo model was developed
based on the preliminary model of rota-
virus burden and immunization cost-
effectiveness described elsewhere (5, 6).
In the Monte Carlo analysis, individual
point estimates of parameters are re-
placed with distributions of potential val-
ues. Individual values are randomly se-
lected from each of the distributions in 
a series of iterations, and results are cal-
culated and stored. A new set of input
values are then randomly selected and 
a new set of results are calculated and
stored. The process is repeated for 10 000
iterations. The final product is a distri-
bution of potential outcomes that de-
scribe the likely range of actual expected
results. 
The output ranges developed through
the uncertainty analysis are included in
Table 2. In addition, the uncertainty
analysis allows us to identify the para-
meters that contribute the most to uncer-
tainty in the outcome estimates. For the
cost-effectiveness analysis, uncertainty
about diarrheal mortality and the por-
tion attributable to rotavirus are addi-
tional key contributors to uncertainty.
RESULTS
Disease burden and risk of rotavirus
outcomes
The estimated disease burden of ro-
tavirus with and without a vaccination
program in Mexico is presented in Table
3. Each year, due to rotavirus AGE, 1 in
4 children less than 5 years of age (265
per 1 000) required a clinic visit; 1 in 140
(7 per 1 000) was hospitalized; and 1 in 
2 500 (0.4 per 1 000) died. An estimated
14 DALYs per 1 000 births were lost to
these outcomes. For the base case, the
TABLE 1. Input variables for a cost-effectiveness analysis of a rotavirus (RV) vaccination program in Mexico
Variables Baseline estimate Data source
a These costs include the direct medical costs of hospitalization, outpatient visits, diagnostic tests, and medication, and are expressed in 2007 US dollars.
Demographics
Birth cohort
Average life expectancy at birth (years)
Male 
Female
Cumulative risk of outcomes for RV gastroenteritis 
per 1 000 children < 5 years
Outpatient visit rate
Hospitalization rate
Mortality rate
Direct medical cost of RV gastroenteritis per patient a
Ambulatory cases
Hospitalized cases
Vaccine
Efficacy (RV outpatient visits)
Efficacy (RV hospitalization)
Efficacy (RV death)
Coverage
Administration cost (per course)
Price per course (2 doses)
2 285 000
73.6
74.4
265
7
0.42
US$ 27.3
US$ 174.2
78%
85%
85%
93%
US$ 1.0
US$ 16.0
PAHO, 2004 (9) 
WHOSIS, 2000 (28)
SSA, 2002 (21); IMSS, 2002 (22); extrapolation of five published studies (23–26)
SSA, 2002 (21); IMSS, 2002 (22); Velázquez et al., 2001/4 (3, 27)
SSA, 2002 (21); assumed RV proportion is the same as hospitalized 
Financial department of Hospital General de Tlalnepantla; physician interviews;
information not published
Ruiz-Palacios et al., 2006 (31); De Vos et al., 2004 (32) 
Ruiz-Palacios et al., 2006 (31)
Assumes efficacy is same as for hospitalizations (31)
CONAVA, 2003–4 (33)
Author’s assumption
Author’s assumption
TABLE 2. Breakeven costs of rotavirus vaccine in Mexico using alternative criteria (best estimate
and range) in 2007 US$
US$ / dose
Best estimate 95% CI
Breakeven cost
Direct, medical price 5.10 4.11–6.66
Retail price (direct, indirect costs) 6.24 5.49–8.47
Cost effectiveness 
gross national product 64.37 50.78–78.94
$1 000 (expanded oral rehydration therapy, water) 11.74 10.02–14.46
$550–800/DALYa (World Bank) 9.15 7.86–11.49
$175/DALY (WHO low income) 5.16 4.44–7.07
$75/DALY (HepB, Hib)b 4.36 3.69–6.26
$30/DALY (Expanded Program on Immunization) 4.00 3.34–5.90
a DALY: disability-adjusted life year.
b HepB: Hepatitis B; Hib: Haemophilus influenza type b.
model predicts that rotavirus AGE is
responsible for an annual 414 927 (182
per 1 000) outpatient visits; 13 833 (6 per 
1 000) hospitalizations; and 651 (0.28 per
1 000) deaths, all of which could be pre-
vented by rotavirus vaccination. This rep-
resents an overall reduction of 69%, 86%,
and 70%, respectively.
Costs of rotavirus disease. Based on the
estimates derived from the hospital-
based rotavirus surveillance study (32),
the total direct medical cost for inpa-
tients was US$ 211, with 92% of the cost
attributed to hospitalization and the re-
mainder due to the cost of diagnostics
and medication. For outpatients, the
total direct medical cost was US$ 27, of
which 55% was attributed to the cost of
the visit (Table 4). 
The costs of treating AGE using the
hospital-based rotavirus surveillance
study were similar to alternative cost-
estimates. In Table 4, the inpatient and
outpatient data estimates are compared
to those using secondary data (WHO-
CHOICE and Children for Vaccine Ini-
tiative cost studies) and physician in-
terviews. The total direct medical cost
for hospitalization ranged from US$ 211,
using the hospital-based surveillance
data, to US$ 311, using secondary data—
a total difference of US$ 100. The differ-
ence between the high- and low-end es-
timates of total direct medical costs for
outpatient visits was US$ 7.24.
The estimated economic burden of ro-
tavirus GE in Mexico and benefits of a
rotavirus vaccine are shown in Table 5.
In the absence of vaccination, it was esti-
mated that rotavirus AGE resulted in a
total health care cost of over US$ 19.6
million for each annual birth cohort,
equivalent to US$ 8.58 per child. Of these
costs, 83% were associated with outpa-
tient visits. Vaccination significantly re-
duced the economic burden of rotavirus
AGE in Mexico, averting US$ 14 million
(71% of the total health care burden).
Cost-effectiveness of the rotavirus vacci-
nation program. The estimates of the
cost-effectiveness of a rotavirus vaccina-
tion program in Mexico are presented in
Table 6, and assume a basic vaccine price
of US$ 16 per course. The cost of the
vaccination program includes the price of
the vaccine and its administration. More-
over, the vaccination program cost as-
sumes only the cost of vaccinating chil-
dren who would receive the vaccine,
based on vaccine coverage estimates and
10% wastage. Benefits are expressed as
net medical costs from the health care sys-
tem perspective and the cost-effectiveness
ratio. All of these cost and benefit mea-
sures vary directly with vaccine price.
At a price of US$ 16 per course (two
doses), it would cost US$ 25.4 million 
to vaccinate the Mexican birth cohort
with the rotavirus vaccine (net medical
costs). From the health care system per-
spective, a rotavirus vaccination pro-
gram costs US$ 1 139 per DALY averted, 
US$ 39 102 per life saved, US$ 1 839 per
hospitalization averted, and US$ 61 per
medical visit averted. Across all course-
costs less than or equal to US$ 16, ro-
tavirus vaccination was projected to be
cost-effective, using the WHO criteria
and a per-capita GDP of US$ 6 121 for
Mexico (40). 
Sensitivity and uncertainty analyses
The results of one-way sensitivity
analyses are presented in Table 7. The es-
timated medical cost per child is most
sensitive to changes in assumptions re-
garding the incidence of rotavirus outpa-
tient visits and the cost of outpatient treat-
ment. A 25% change in either of those
parameters results in 11–21% change in
the medical cost per child. The incre-
mental cost-effectiveness rate estimates
are affected by the rotavirus mortality
rate, vaccine efficacy against mortality,
and vaccine price. A 25% change in any of
these variables results in 8–41% change 
in the incremental cost-effectiveness ratio.
In addition, assuming a vaccine efficacy
TABLE 3. Estimated disease burden of rotavirus in Mexico with and without a rotavirus
vaccination program
Events per
Total annual events 1 000 children
Without vaccination
Outpatient visits 605 525 265
Hospitalizations 16 086 7
Deaths 923 0.40
DALYsa 31 768 14
With vaccination
Outpatient visits 190 598 83.41
Hospitalizations 2 253 0.99
Deaths 273 0.12
DALYsa 9 436 4.13
Benefit of vaccination (averted events)b
Outpatient visits 414 927 181.59
Hospitalizations 13 833 6.05
Deaths 651 0.28
DALYsa 22 331 9.77
a Disability-adjusted life years discounted at 3%.
b Benefit of vaccination is based on the vaccine effectiveness, which incorporates information on the vaccine effi-
cacy and coverage.
TABLE 4. Comparison of direct medical costs of treating gastroenteritis in Mexico using the
hospital-based rotavirus surveillance study and alternative data, in 2007 US$
Hospital-based
surveillance Alternative Alternative
(US$) data (US$) 1a (US$) 2b
Hospitalization
Per-diem cost 57.45 66.83 57.45
Length of stay (days) 3.4c 3.5 4.0
Total hotel cost 195.32 233.91 229.80
Diagnostics/medications 15.90 77.19 27.04
Total direct cost/hospitalization 211.22 311.10 256.84
Outpatient visit 
Hotel cost 14.99 17.03 14.99
Diagnostics/medications 12.24 11.07 5.87
Total direct cost/outpatient visit 27.23 28.10 20.86
a Alternative 1: WHO-CHOICE and CVI data. These values were originally based on 2002 prices and were adjusted for in-
flation using the Consumer Price Inflation index (41).
b Alternative 2: Physician interview data.
c Average of 2.8 days (hospital-based surveillance study) and 4 days (physician interviews).
of 73% against AGE from any cause im-
proved cost-effectiveness, as reflected by
the lower cost-effectiveness ratio for Mex-
ico. In general, an increase in rotavirus in-
cidence and vaccine efficacy will result in
a lower incremental cost-effectiveness ra-
tio making a vaccination program more
cost-effective. Furthermore, a reduction
in the price of the rotavirus vaccination
program (US$ 8 per dose) will yield a
lower incremental cost-effectiveness ratio
of US$ 303 per DALY averted. 
For the uncertainty analysis, the cost-
effectiveness of vaccination using the
baseline and alternative scenarios is
shown in Figure 2. The graph shows the
cost effectiveness (US$/DALY) at differ-
ent vaccine price levels for each of the
scenarios. The point at which each line
crosses the horizontal access is the break-
even price (medical cost). The break-even
cost per dose, i.e., the cost per dose below
which the vaccine became cost-saving,
was US$ 5.10 per course in an analysis
that considered health care system costs
alone. The figure does not consider the
combined impact of the scenarios.
DISCUSSION
This is the first economic evaluation of
the impact that a national rotavirus vac-
cination program would have on chil-
dren in Mexico. Morbidity and mortality
data were derived from national admin-
istrative data and efficacy data from the
most recent results of the phase III effi-
cacy trial of the live-attenuated human
rotavirus vaccine performed in Latin
TABLE 5. Estimated economic burden of rotavirus-related gastroenteritis and benefits of a rota-
virus vaccination program in Mexico, in 2007 US$
Direct medical costsa Mean cost per childa,b
(US$) (US$)
Without vaccination
Outpatient visits 16 273 770 7.12
Hospitalizations 3 326 828 1.46
Total 19 600 598 8.58
With vaccination
Outpatient visits 5 127 904 2.24
Hospitalizations 467 380 0.20
Total 5 595 284 2.44
Benefit of vaccination (averted costs)c
Outpatient visits 11 145 866
Hospitalizations 2 859 448
Total 14 005 314
a The total discounted direct medical costs for a given birth cohort was calculated as the sum of costs for all facility types and
age groups, adjusting future financial outcomes for the cohort back to a present value. The discounted costs were based on
hospital-based surveillance data (US$ 2007).
b Calculation only includes direct medical costs to the health care system and pertains to the direct medical costs that each child
under-5 years incurs as a result of a rotavirus infection.
c Benefit of vaccination is based on the vaccine effectiveness, which incorporates information on the vaccine efficacy and
coverage.
TABLE 6. Estimates of costs, net benefits and
cost-effectiveness of a rotavirus vaccination
program in Mexico, in 2007 US$
Vaccine program costa US$b
Vaccine administration 2 120 480
Vaccine ($16/course) 37 320 448
Total cost 39 440 928
Averted medical costs 14 005 314
Net medical direct cost 25 435 613
Incremental cost-effectiveness ratio
Cost per DALYc averted 1 139
Cost per life saved 39 102
Cost per hospitalization averted 1 839
Cost per medical visit averted 61
a Vaccination cost assumes only the cost of vaccinating chil-
dren who would receive the vaccine, based on vaccine
coverage estimates and 10% wastage.
b The intervention cost, net medical cost and incremental
cost-effectiveness ratio (US$/DALY) assume a vaccine
price of US$ 16 per course. Values are based on hospital-
based surveillance data (US$ 2007).
c DALY: disability-adjusted life year.
TABLE 7. The effect of rotavirus incidence, vaccine efficacy, and cost estimates on the medical
cost attributed to rotavirus disease and the cost-effectiveness of a rotavirus vaccination program
in Mexico, in 2007 US$
Incremental cost-effectiveness
Medical cost per child ratioa (US$)
Variable US$ Change % Change %
5-year cumulative risk of hospitalization 
due to RV GEb
0.005 (–25%) 7.22 –4 1 150 +1
0.007c 7.54 1 139
0.009 (+25%) 7.87 +4 1 128 –1
5-year cumulative risk of death due to 
RV GE (× 100 000)
30.3 (–25%) No 1 515 +33
40.4c 7.54 1 139
50.5 (+25%) No 911 –20
5-year cumulative risk of an outpatient visit
due to RV GE
0.199 (–25%) 5.98 –21 1 207 +6
0.266c 7.54 1 139
0.331 (+25%) 9.11 +21 1 071 –6
Vaccine efficacy (deaths averted)
0.80 (–14%) No 1 298 +14
0.92c 7.54 1 139
1.00 (+8%) No 1 048 –8
Vaccine efficacy (hospitalization averted)
0.80 (–14%) No 1 150 +1
0.92c 7.54 1 139
1.00 (+8%) No 1 139 0
Hospitalization per-diem cost
38.24 (–25%) 7.25 –4 1 150 +1
50.98c 7.54 1 139
63.73 (+25%) 7.84 +4 1 128 –1
Outpatient visit cost
9.98 (–25%) 6.69 –11 1 173 +3
13.30c 7.54 1 139
16.63 (+25%) 8.41 +11 1 105 –3
Vaccine price ($/course)
$16 (–33%) No 1 606 –41
$24c 7.54 1 139
$32 (+33%) No 672 +41
a The incremental cost-effectiveness ratio (US$/disability-adjusted life year) assumes a vaccine price of US$ 24.00 per course
unless specified otherwise.
b RV GE: rotavirus-related gastroenteritis.
c Base case scenario.
America, including Mexico (32). Rota-
virus AGE results in a significant disease
and economic burden from the perspec-
tive of the Mexican health care system.
Rotavirus vaccination would prevent
70% of deaths due to rotavirus, 86% of
associated hospitalizations, 69% of out-
patient visits, and 70% of the associated
DALYs. This compares to rates observed
in other Latin American countries where
rotavirus-associated mortality rates are
lower (46, 47). Vaccination would also
result in total, direct medical savings of
US$ 14 million, 71% of the overall health
care burden (burden of all diseases).
Several criteria can be used for eco-
nomic evaluations of a vaccination pro-
gram. The appropriateness of the different
approaches depends on the perspec-
tive of the policymaker. As an approxi-
mate benchmark and for comparison
purposes only, we used the per-capita
Gross Domestic Product (GDP) as a
threshold and assumed that vaccination
strategies that were less than this bench-
mark were potentially very cost-effective
(46). With a per capita GDP of US$ 6 121
for Mexico (40) and a vaccine price of 
US$ 16 per course, a national rotavirus
vaccination program for Mexican chil-
dren would be considered a very cost-
effective intervention since the cost per
DALY averted is US$ 1 139. It is impor-
tant to emphasize that even if vaccination
can be cost-effective, i.e., that the incre-
mental cost-effectiveness ratio is less than
the per capita GDP of a specific country, 
it may not be affordable without assis-
tance. Future studies should focus their
efforts on providing estimates of the fi-
nancial costs to vaccinate a single birth co-
hort at different coverage rates. 
Another criterion frequently used by
national decision-makers is to compare
the cost-effectiveness of a health inter-
vention to the cost-effectiveness of other
similar health interventions; in this case,
other strategies for diarrhea prevention,
child nutrition, and immunization. Ide-
ally, the most cost-effective intervention
would be chosen first. However, this
type of country-specific information is
not available in Mexico. Even if this in-
formation were available, comparing
data across studies must be done with
caution since there may be differences in
the methods used. 
Our analysis integrated empirically-
collected country-specific cost data with
country-specific epidemiological esti-
mates to develop the first national eco-
nomic model of rotavirus vaccine intro-
duction in Mexico. It complements other
Regional efforts to develop further un-
derstanding of the value of a rotavirus
vaccination program. These include two
Regional studies (5, 6) and six country-
level studies (46–51) that describe the
disease and economic burden of rota-
virus, and estimate the benefit and cost-
effectiveness of rotavirus vaccination at
the Regional and country-levels. 
A few study limitations need to be
borne in mind. As shown by the sensi-
tivity analysis, the rotavirus mortality
rate and vaccine efficacy against death
greatly affect the cost-effectiveness of
vaccination. Although these variables are
important to the results of the analysis,
they have not been directly evaluated.
Diarrheal deaths are generally recorded;
however, vital statistics do not register
the primary cause of diarrhea death as
rotavirus. Moreover, the proportion of
diarrheal deaths due to rotavirus is
unknown. For this reason, it assumed
that the proportion would be similar to
hospitalized cases. Likewise, vaccine ef-
ficacy against death has been assumed 
to be the same as that for hospitalized
cases, because death has not been eval-
uated as an outcome of a vaccine trial.
Efforts should be made to empirically
ascertain the incidence of death due to
rotavirus AGE using active surveillance,
especially in areas of the country where
there is limited access to emergency
treatment facilities.
The sensitivity analysis also demon-
strated that the evaluation of health care
resource utilization and its ascribed costs
impact the health care costs associated
with rotavirus AGE. Despite uncertainty
in health care costs, the sensitivity analy-
sis shows that varying costs by 25% has
almost no effect on the cost-effectiveness
of vaccination. Considering a societal per-
spective would therefore have made no
difference in the cost-effectiveness of
vaccination. Since it is possible that a
child with AGE had a co-infection that
required additional medications and di-
agnostic tests, there is some uncertainty
about the actual cost of treating AGE. To
avoid overestimating the medication
and diagnostic costs, only the medi-
cations and diagnostic tests commonly
used to treat AGE were included in the
analysis. However, there is no way to be
certain whether a specific antibiotic was
prescribed to treat AGE or some other
infection. 
Another limitation is related to the
availability of data on rotavirus disease
treatment costs. Estimates of resource
utilization were developed using a sam-
ple population in select facilities and
medical treatment costs were derived
from only one hospital. However, costs
were varied by 25% in the sensitivity
analysis. The sensitivity analysis shows
that varying costs by 25% has almost no
effect on the cost-effectiveness of vacci-
nation. Alternative cost estimates were
described in the paper for comparison,
but were not used in the sensitivity
analysis because there was uncertainty
about the various methods used to de-
rive these estimates.
In addition, outpatient visits were the
main contributor to medical costs; how-
ever, outpatient and emergency room vis-
its remain difficult to ascertain, espe-
cially because rotavirus AGE is not
easily diagnosed in these settings in
FIGURE 2. Cost-effectiveness of rotavirus vaccination in Mexico for alternative scenarios, in 
2007 US$
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Mexico. These estimates could be im-
proved with additional data and larger
samples. 
Additional study limitations are re-
lated to the coverage rate and timing of
vaccination. Vaccine coverage is the
proportion of children less than 5 years
of age who would receive the rotavirus
vaccine. The coverage is based on cover-
age rates of other vaccines (e.g., DTPa,
Hib+IPV, and HBV), which may not be
an accurate estimation of rotavirus vac-
cine coverage if a vaccine were to be in-
troduced. In the analysis, we assumed
that all groups within the country have
equal likelihood of vaccination and all
children would receive the vaccine at the
recommended time. If high-risk popula-
tions were missed or vaccination were
delayed, the effectiveness would be re-
duced. Since rotavirus GE occurs in
young children and protection is con-
ferred from the time of vaccine dose 1
until dose 2 is given (32), it is important
that the vaccine be given on time. Future
considerations should be made to ac-
count for the fact that not all children
will receive the vaccine at the recom-
mended time.
A final limitation of the study is the
lack of data on the magnitude of herd
immunity, which may be conferred by
partial coverage of vaccination into a
population. The analysis considered the
direct effects of vaccination, but it did not
consider the indirect protective effect on
persons never vaccinated. The herd im-
munity effect could be large and might
offset inefficiencies in delivery of a com-
plete course, and on-time vaccination to
all children. 
In summary, rotavirus AGE results in
a significant disease and economic bur-
den in Mexican children. The results of
this evaluation provide to policymak-
ers strong evidence that supports the
implementation of a national mass ro-
tavirus vaccination program as a very 
cost-effective health care intervention in
Mexico.
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